コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 resistance and severe cardiotoxicity (e.g., congestive heart failure).
2 adverse events (grade 2 fatigue and grade 4 congestive heart failure).
3 potension, bradycardia, bronchospasm, and/or congestive heart failure).
4 med angina, silent MI, revascularization, or congestive heart failure).
5 ent with pacemaker syndrome, and 1 developed congestive heart failure.
6 seases, such as ventricular fibrillation and congestive heart failure.
7 ass index, ejection fraction, and history of congestive heart failure.
8 ation are at an increased risk of developing congestive heart failure.
9 tant tool for the diagnosis and treatment of congestive heart failure.
10 chexia is a life threatening complication in congestive heart failure.
11 prematurity, sleep disordered breathing and congestive heart failure.
12 ated to the chronic conditions of asthma and congestive heart failure.
13 k between the abdomen, heart, and kidneys in congestive heart failure.
14 rdiomyopathies, which are a leading cause of congestive heart failure.
15 s required in 23 patients, mainly because of congestive heart failure.
16 cular events, peripheral artery disease, and congestive heart failure.
17 fluid retention, weight gain, bone loss and congestive heart failure.
18 orrelated with renal dysfunction in advanced congestive heart failure.
19 blood pressure, hypertension treatment, and congestive heart failure.
20 al fibrillation, ischemic heart diseases, or congestive heart failure.
21 e consisting of death, reinfarction, and new congestive heart failure.
22 were male; 13% had had a stroke; and 45% had congestive heart failure.
23 Captopril, which is generally used to treat congestive heart failure.
24 ute myocardial infarction and for those with congestive heart failure.
25 nary artery disease, arrhythmias, stroke, or congestive heart failure.
26 prevention of DOX-induced cardiotoxicity and congestive heart failure.
27 of grade 3 neuropathy, and 2 had symptomatic congestive heart failure (0.5%; 95% CI, 0.1 to 1.8), bot
28 ; HR: 1.18; 95% CI: 1.04 to 1.34; p = 0.01), congestive heart failure (107 events; HR: 1.25; 95% CI:
29 6-3.69), high-risk surgery 2.70 (2.46-2.96), congestive heart failure 2.65 (2.29-3.06), cerebrovascul
30 lized for acute myocardial infarction (19%), congestive heart failure (25%), pneumonia (30%), and con
31 04), stroke (2.43% vs. 1.93%; p = 0.05), and congestive heart failure (3.75% vs. 2.25%; p < 0.0001) t
33 -20.4%), cardiac dysrhythmias (21.7%-29.0%), congestive heart failure (40.7%-56.1%), acute (5.9%-20.1
34 r dysfunction, but blacks had more prevalent congestive heart failure (43% versus 34%; P=0.04) and le
35 ry disease (26.6 to 12.6% of admissions) and congestive heart failure (8.5 to 5.4% of admissions).
37 ance of the cardenolides in the treatment of congestive heart failure, a variety of ouabagenin analog
38 ascular events, and disease-specific events: congestive heart failure, acute myocardial infarction, a
39 OR: 0.36; 95% CI: 0.31 to 0.42; p < 0.001), congestive heart failure (adjusted OR: 0.82; 95% CI: 0.7
42 et the composite end point (48 deaths and 19 congestive heart failure admissions, 2.5% 30-day deaths)
43 s were more likely to have had AKI, multiple congestive heart failure admissions, and other hospitali
45 revention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarcti
46 were to identify correlates of mortality and congestive heart failure after aortic valve replacement
48 er age, White race, coronary artery disease, congestive heart failure, alcoholism, proteinuria, reduc
49 ncidence of coronary artery disease, stroke, congestive heart failure, all-cause mortality, and cardi
50 s ago, are used to treat hypertension and/or congestive heart failure, although there are therapeutic
51 vent (heart attack, stroke, new or worsening congestive heart failure, amputation for ischemic gangre
52 to the emergency department with symptoms of congestive heart failure and a 1-week history of chest p
53 Dilated cardiomyopathy is a leading cause of congestive heart failure and a debilitating complication
54 radation of cardiac control in patients with congestive heart failure and a more degradation in criti
55 ing hospitalization for sepsis compared with congestive heart failure and acute myocardial infarction
56 readmissions following sepsis compared with congestive heart failure and acute myocardial infarction
57 ative to other high-risk conditions, such as congestive heart failure and acute myocardial infarction
62 arison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [ST
63 re embryonic day 9; TnT/Isl1-Cre) results in congestive heart failure and death by embryonic day 11.5
65 g dialysis patients, warfarin users had more congestive heart failure and diabetes mellitus, but fewe
66 h as sleep-disordered breathing with apnoea, congestive heart failure and essential hypertension.
67 also compared for patients with a history of congestive heart failure and for patients aged >/=80.
68 ,946), CTDN was superior to HCTZ in reducing congestive heart failure and in reducing all CVEs: perce
69 requent; however, exacerbation of asthma and congestive heart failure and one fatal cerebral hemorrha
70 and (2) patients in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz
72 t Failure Score, ESCAPE [Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz
73 portions of the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz
75 ase 2, 32 participants (including those with congestive heart failure and pulmonary hypertension) use
76 ment of the pathophysiology of congestion in congestive heart failure and the methods by which we det
77 0 million/yr for sepsis, $229 million/yr for congestive heart failure, and $142 million/yr for acute
78 22.9%; interquartile range, 19.2-26.6%) for congestive heart failure, and 3.6% to 40.8% (median, 17.
79 tes were 20.4%, 23.6%, and 17.7% for sepsis, congestive heart failure, and acute myocardial infarctio
80 litus, hypertension, cardiovascular disease, congestive heart failure, and advanced chronic kidney di
83 outcomes were myocardial infarction, stroke, congestive heart failure, and cardiovascular mortality.
84 ey role in the pathogenesis of hypertension, congestive heart failure, and chronic kidney disease.
85 ge, female sex, Medicare or State insurance, congestive heart failure, and chronic kidney disease.
86 nce of death, myocardial infarction, stroke, congestive heart failure, and fractures, were compared d
88 age, sex, race, diabetes status, presence of congestive heart failure, and hemoglobin, serum albumin,
90 FDCM and IDCM but for both groups older age, congestive heart failure, and increased left ventricular
91 ng age, male gender, pulmonary hypertension, congestive heart failure, and liver disease are risk fac
92 composite primary end point of death, shock, congestive heart failure, and reinfarction when compared
93 increased risk for death, cardiac death, and congestive heart failure, and subjects presenting PTF >/
94 strongly influenced by severe liver disease, congestive heart failure, and weight, factors that shoul
95 er secondary events including hip fractures, congestive heart failure, angina, falls, depression, cho
97 re likely to have had a primary diagnosis of congestive heart failure at the time of index admission,
98 pitalized for acute myocardial infarction or congestive heart failure but not among those hospitalize
99 in patients with coronary artery disease and congestive heart failure, but clinical use of CPX in oth
100 dialysis duration, peritoneal dialysis, and congestive heart failure, but not diabetes mellitus.
101 , chronic obstructive pulmonary disease, and congestive heart failure) by using the Cox proportional
102 he in-hospital composite end point of death, congestive heart failure, cardiogenic shock, and reinfar
103 older and were more likely to have comorbid congestive heart failure, cardiomyopathy, cerebrovascula
104 f acute myocardial infarction cases, 1.7% of congestive heart failure cases, and 5.8% of stroke cases
105 associated with greater risk of adjudicated congestive heart failure (CHF) and atherosclerotic event
106 mplication of many chronic diseases, such as congestive heart failure (CHF) and chronic kidney diseas
112 valence of mental stress-induced ischemia in congestive heart failure (CHF) patients is unknown.
114 -myocardial infarction use of beta-blockers; congestive heart failure (CHF) with use of angiotensin-c
115 all episodes of myocardial infarction (MI), congestive heart failure (CHF), abdominal aortic aneurys
117 admissions for ischemic heart disease (IHD), congestive heart failure (CHF), and overall CVD were obt
119 echolamine stimulation during development of congestive heart failure (CHF), chronic activation of Gs
120 years included panel-reactive antibody >10%, congestive heart failure (CHF), delayed graft function,
121 ital arrhythmias, eclampsia or preeclampsia, congestive heart failure (CHF), length of stay, preterm
122 m from cardiology, neurology and psychiatry: Congestive Heart Failure (CHF), Major Depression Disorde
123 patients without cirrhosis and patients with congestive heart failure (CHF), matched for age, sex, an
124 rate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease
125 tions for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether
126 tions for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether
127 hospitalization or emergency room visit for congestive heart failure (CHF), outpatient diagnosis of
128 on (MI), other ischemic heart disease (IHD), congestive heart failure (CHF), stroke, chronic kidney d
136 percent of clopidogrel-treated patients with congestive heart failure, cholecystectomy, and lower per
137 scular disease, peripheral vascular disease, congestive heart failure, chronic obstructive pulmonary
138 PE that had no corresponding comorbidities, congestive heart failure, chronic pulmonary disease, coa
139 ary outcomes were hospitalization because of congestive heart failure, coronary heart disease, new on
140 um concentrations, as occur in patients with congestive heart failure, could activate the PKD1/HDAC5/
142 ardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke
143 rior stroke, older age, atrial fibrillation, congestive heart failure, diabetes mellitus, myocardial
148 ing 39 238 person-years; in ARIC, 330 events congestive heart failure events occurred during 64 438 p
149 ar events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or ca
151 0-day death or combined endpoint (defined as congestive heart failure >/= New York Heart Association
152 The top hospital quartile of ICU use for congestive heart failure had a sensitivity of 50-60% and
153 sympathetic overstimulation in patients with congestive heart failure have a negative inotropic effec
155 earts and paroxysmal AF, although those with congestive heart failure have the greatest potential ben
156 astolic dysfunction without the diagnosis of congestive heart failure (HF) and with normal systolic f
157 event the rare, but serious, complication of congestive heart failure (HF) associated with anthracycl
158 .05-1.44), thromboembolism 1.32 (1.17-1.49), congestive heart failure HR 1.57 (1.39-1.78), depression
159 infarction (HR, 0.77; 95% CI, 0.54-1.10) and congestive heart failure (HR, 1.22; 95% CI, 0.84-1.82) d
160 6; 95% confidence interval [CI], 1.80-3.11), congestive heart failure (HR, 2.16; 95% CI, 1.70-2.72),
161 o clinical risk factors and the CHA2DS2VASc (congestive heart failure, hypertension, 75 years of age
162 dicting major bleeding compared with CHADS2 (congestive heart failure, hypertension, 75 years of age
163 transient ischemic attack) and CHA2DS2-VASc (congestive heart failure, hypertension, 75 years of age
164 Clinical schemas, such as the CHA2DS2-VASc (congestive heart failure, hypertension, age >/= 75 years
167 er PVI in association with the CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years
168 After adjustment for the CHA2DS2-VASc score (congestive heart failure, hypertension, age >/=75 years
170 oint on the stroke risk scheme CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,
171 sk patients, i.e., with 0 or 1 CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,
172 ith atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >/=75 years,
173 nd bleeding risks were assessed by using the congestive heart failure, hypertension, age >/=75 years,
174 over established risk stratification scores (congestive heart failure, hypertension, age >/=75 years,
175 ears, diabetes, previous stroke [CHADS2] and congestive heart failure, hypertension, age >/=75 years,
176 patient population with predominant CHADS2 (Congestive heart failure, Hypertension, Age >/=75 years,
177 0 patients with nonvalvular AF and CHADS(2) (congestive heart failure, hypertension, age >/=75 years,
179 African-American ethnicity to CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,
180 h atrial fibrillation (AF) with a "low-risk" congestive heart failure, hypertension, age >/=75, diabe
181 erformance of ATRIA to that of CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75, diabe
182 sk factors, as measured by the CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75, diabe
184 been introduced to complement the CHADS(2) (Congestive heart failure, Hypertension, Age >75 years, D
185 years, 79% were male, and 14% had CHADS(2) [Congestive heart failure, hypertension, Age >75, Diabete
186 in CHA2DS2-VASc score (a risk score based on congestive heart failure, hypertension, age 75 years or
188 e in subjects with ESVEA and a CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or
189 average age of 70+/-12 years, a mean CHADS2 (congestive heart failure, hypertension, age>75, diabetes
190 alvular atrial fibrillation (AF) and CHADS2 (congestive heart failure, hypertension, age, diabetes me
191 roke and bleeding risk were calculated using congestive heart failure, hypertension, age, diabetes me
192 with severe cardiovascular diseases such as congestive heart failure, hypertension, and myocardial f
194 risk factors (diabetes mellitus, history of congestive heart failure, hypertension, or age older tha
195 ted in clinical studies for the treatment of congestive heart failure, hypertension, or diabetic neph
196 ted with CKD in individual CHA(2)DS(2)-VASc (Congestive heart failure; Hypertension; Age >/=75 years;
197 etary sources, were associated with incident congestive heart failure in 2 independent cohorts, sugge
198 ctive biomarkers of exposure, with incidence congestive heart failure in 2 independent cohorts: 3694
199 positively associated with greater incident congestive heart failure in both CHS and ARIC; hazard ra
201 ac events at 90 days with significantly less congestive heart failure in the intracoronary abciximab
203 ting as asymptomatic cardiac dysfunction and congestive heart failure in up to 57% and 16% of patient
204 Two hundred and four (6.9%) patients had new congestive heart failure (incidence, 38.42/1000 patient-
207 relatively early stages, the abrupt onset of congestive heart failure is uncommon and should raise su
209 patients with cardiovascular disease such as congestive heart failure, ischemic heart disease, valvul
210 -eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein
211 included young age, low weight, presence of congestive heart failure, lower left ventricular fractio
213 l in which weight, severe liver disease, and congestive heart failure most affected fentanyl concentr
214 he primary safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of
215 ac respiratory failure, atrial fibrillation, congestive heart failure, myocardial infarction, and reo
217 tient with a history of atrial fibrillation, congestive heart failure (NYHA II/III), stable coronary
218 sease (odds ratio, 1.22; 95% CI, 1.11-1.34), congestive heart failure (odds ratio, 1.14; 95% CI, 1.08
219 cardiac end point was defined as symptomatic congestive heart failure of New York Heart Association c
220 ction, stroke, gastrointestinal bleeding, or congestive heart failure or a Diagnosis Related Group cl
221 infarction, coronary artery bypass grafting, congestive heart failure or abdominal aortic aneurysm, g
222 thin the categories of sudden death, cancer, congestive heart failure or chronic lung disease, and fr
223 in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.
224 The risk of new MI, being admitted with congestive heart failure or death, increased with increa
225 ization was more pronounced in patients with congestive heart failure or ischemic heart disease than
226 ization was more pronounced in patients with congestive heart failure or ischemic heart disease than
228 reast cancer, except for those with clinical congestive heart failure or significantly compromised le
229 llation (OR, 0.82; CI, 0.70-0.95; P = 0.01), congestive heart failure (OR, 0.73; CI, 0.60-0.88; P < 0
230 22; 95% CI, 1.00-1.48; P = .045), history of congestive heart failure (OR, 1.25; 95% CI, 1.12-1.39; P
231 liver disease (OR, 1.57; 95% CI, 1.39-1.77); congestive heart failure (OR, 1.49; 95% CI, 1.38-1.61);
233 athy, by characteristics such as low weight, congestive heart failure, or abnormal echocardiographic
234 9.8) and the combination end point of death, congestive heart failure, or cardiogenic shock at 90 day
235 Patients with preexisting diabetes mellitus, congestive heart failure, or chronic or acute renal fail
236 infarction, acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) seriou
237 eficiaries with acute myocardial infarction, congestive heart failure, or pneumonia, 30-day mortality
238 y end point was a composite of death, shock, congestive heart failure, or reinfarction up to 30 days.
239 y revascularisation, hospital admission with congestive heart failure, or stroke, which was assessed
240 rmed HCM presented with rapid development of congestive heart failure over 6 months, in sharp contras
241 (P </= 0.04), heart attack (P </= 0.01), and congestive heart failure (P </= 0.02), but not with stro
242 P<0.001), pulmonary hypertension (P<0.0001), congestive heart failure (P=0.0008), and liver disease (
244 contained 10 categorical variables including congestive heart failure, paraplegia, reoperation, dyspn
246 comitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial da
247 05 and 2011 for acute myocardial infarction, congestive heart failure, pneumonia, or conditions requi
249 gnosis at index AKI hospitalization included congestive heart failure (primary diagnosis), decompensa
250 dial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficienc
251 ard Medical therapy in Elderly patients with Congestive Heart Failure randomized 499 patients with HF
252 er the inclusion of an SES measure in 30-day congestive heart failure readmission models changed hosp
253 y mass index, noncardiac surgery, history of congestive heart failure, renal disease, existing airway
254 t disease (RR, 4.31; 95% CI, 3.38-5.49), and congestive heart failure (RR, 2.05; 95% CI, 1.29-3.25).
256 de prostate and breast cancers, uncontrolled congestive heart failure, severe lower-urinary-tract sym
257 nute walk test (6MWT) independently predicts congestive heart failure severity, death, and heart fail
258 us thromboembolism, coronary artery disease, congestive heart failure, sleep-disordered breathing, ga
259 -salt diet, a model for hypertension-induced congestive heart failure, spermidine feeding reduced sys
260 llowed them for 2 years to assess mortality, congestive heart failure, stroke or transient ischemic a
261 s also been linked to myocardial infarction, congestive heart failure, stroke, and diabetes mellitus
262 al infarction, coronary heart disease death, congestive heart failure, stroke, incident angina, or in
264 ical diagnoses (acute myocardial infarction, congestive heart failure, stroke, pneumonia, and chronic
265 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure Study (TACTICS) and Study to Ev
266 f Mechanical Assistance for the Treatment of Congestive Heart Failure) study experience, readmissions
267 Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure) study was conducted to address
268 A multivariable model-including angina, congestive heart failure symptoms, shockable arrest rhyt
269 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT01644331).
271 ior stroke, hypertension, renal disease, and congestive heart failure than white men but lower rates
272 kg and no history of severe liver disease or congestive heart failure, the final model, which perform
275 and systemic right ventricles have premature congestive heart failure; there is also a growing concer
276 eing completely asymptomatic; to features of congestive heart failure to vaginal bleeding which may a
277 s (172 women) in the Atrial Fibrillation and Congestive Heart Failure Trial completed the Anxiety Sen
281 .0; 95% confidence interval [CI], 4.8-13.5), congestive heart failure (unadjusted HR, 3.2; 95% CI, 1.
283 ial infarction, or serious adverse events of congestive heart failure, unstable angina, or arrhythmia
284 of myocardial infarction, stroke, or severe congestive heart failure using the National Health and N
285 he relative risk of coronary artery disease, congestive heart failure, valvular heart disease, perica
286 s, including hypertension, cardiac fibrosis, congestive heart failure, ventricular remodeling, and di
287 visits with 17alpha(H),21beta(H)-hopane and congestive heart failure visits with elemental carbon.
288 risk score PANWARDS (platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic
289 tio, 11.42 [95% CI, 10.93-11.93]; P < .001); congestive heart failure was a negative correlatefold (o
290 terval, 4.73-89.53; P=0.0001) and history of congestive heart failure was also significantly associat
293 schemic attack, prior systemic embolism, and congestive heart failure were associated with more frequ
294 ty, age >/= 75 years, history of stroke, and congestive heart failure were found to be independent pr
295 articipants, but not seniors, and those with congestive heart failure were less likely to achieve a 2
296 of major ischemic cardiovascular events and congestive heart failure were not significantly differen
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。